Compare RM & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | DCTH |
|---|---|---|
| Founded | 1987 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 350.7M |
| IPO Year | 2012 | N/A |
| Metric | RM | DCTH |
|---|---|---|
| Price | $37.58 | $10.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.00 | $22.60 |
| AVG Volume (30 Days) | 43.5K | ★ 448.2K |
| Earning Date | 02-04-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 71.26 | N/A |
| EPS | ★ 4.13 | 0.03 |
| Revenue | ★ $610,145,000.00 | $79,603,000.00 |
| Revenue This Year | $16.34 | $132.21 |
| Revenue Next Year | $7.05 | $33.88 |
| P/E Ratio | ★ $9.29 | $318.21 |
| Revenue Growth | 9.60 | ★ 251.54 |
| 52 Week Low | $25.41 | $8.12 |
| 52 Week High | $46.00 | $18.23 |
| Indicator | RM | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 60.25 |
| Support Level | $35.99 | $10.05 |
| Resistance Level | $38.75 | $11.15 |
| Average True Range (ATR) | 1.28 | 0.41 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 24.45 | 68.07 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.